Eli Lilly faces Q1 sales headwinds as incretin gains offset by weakness in other drugs
Tweet Send to a Friend
Eli Lilly and Co. may face a challenging first quarter, with analysts at Wells Fargo Securities projecting a potential 2 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
